A Phase 2 interventional study of Alendronate and Zoledronic Acid in IOP and Osteoporosis, sponsored by Columbia University. Completed at 2 sites in United States. Open to female participants aged 20 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by Columbia University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.
Among the 51 studies testing alendronate in Osteoporosis, this one is the 42nd largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 2, and was the 45th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Women only
Paul F Netzel · Sites in United States
Ages 45+ · Women only
By country, each count listing its studies:
Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 15 · Phase 4 17
First in 1997; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 60 across the 51 interventional studies. Of the 42 that completed or were terminated, 18 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 149 (82%) have results posted.
10 studies in Osteoporosis by Columbia University: none open now, 1 under way, none of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 10 studies in Osteoporosis by Columbia University, this one is the only one that started in 2018, is one of 2 in phase 2, and was the 9th registered.
Columbia University’s Osteoporosis studies by the year they started, since 1997.
1 of the studies testing alendronate in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing alendronate in Osteoporosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Columbia University’s 10 in Osteoporosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary goal of the study is to assess the extent to which bisphosphonate therapy will prevent decreases in bone mass that may occur after cessation of denosumab in premenopausal women with idiopathic osteoporosis (IOP) enrolled in AAAN0161 (FD05114) "Denosumab for the prevention of post-teriparatide bone loss in premenopausal women with idiopathic osteoporosis".
In addition, the investigator will observe participants for a second year off bisphosphonate therapy to assess duration of response.
The hypothesis is that bisphosphonate therapy with alendronate or zoledronic acid, initiated after recovery of bone remodeling activity, will prevent significant bone loss after discontinuing denosumab.
Osteoporosis in premenopausal women with normal menstrual function and no specific cause is termed idiopathic osteoporosis (IOP). IOP is a rare disease with an estimated prevalence of \<200,000 affected premenopausal women in the United States.
Women with IOP completing at least one year and up to three years of denosumab (Protocol AAAN0161) will be offered participation in this open-label study in which they would choose whether to take oral alendronate 70 mg weekly for 12 months or a single intravenous dose of zoledronic acid 5 mg. Subjects and study personnel will be blinded to BMD outcomes until 12 months.
Discontinuation of denosumab is followed by substantial increases in bone turnover markers to well above baseline, bone resorption reaching twice baseline levels for about 6 months. Over the first 12 months off therapy, all the bone density gained on treatment is lost. Studies done at the institution has demonstrated the occurrence of multiple vertebral fractures in some patients who have stopped denosumab. Based upon these new fracture data, the Prolia label is currently recommending that consideration should be given to transition to another antiresorptive drug in patients stopping denosumab. The main goals of this extension study are to determine rates of bone loss and incidence of radiographic vertebral fractures during one year of bisphosphonate therapy (oral alendronate or intravenous zoledronic acid) initiated after completing denosumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to bisphosphonate treatment:
Abnormal laboratory tests performed during Visit 1
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive oral alendronate
Drug: Alendronate
Subjects will receive zoledronic acid
Drug: Zoledronic Acid
oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
Also known as: fosamax
single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
Also known as: Reclast
Difference in BMD at the Lumbar Spine (L1-4) Within Group
Within-group difference (percent change) in BMD at the lumbar spine (L1-4) will be measured by Dual-energy X-ray absorptiometry (DXA) and calculated.
Time frame: Baseline, 12 month
| Milestone | Alendronate | Zoledronic Acid |
|---|---|---|
| Started | 18 | 6 |
| Completed | 18 | 6 |
| Not completed | 0 | 0 |
Within-group difference (percent change) in BMD at the lumbar spine (L1-4) will be measured by Dual-energy X-ray absorptiometry (DXA) and calculated.
| percentage of change | Alendronate | Zoledronic Acid |
|---|---|---|
| Difference in BMD at the Lumbar Spine (L1-4) Within Group | -1.1 ± 4.8 | -2.4 ± 1.0 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alendronate | 0/18 (0%) | 0/18 (0%) | 12/18 (66.7%) |
| Zoledronic Acid | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Alendronate | Zoledronic Acid |
|---|---|---|
| Acute phase reactionImmune system disorders | 0/18 | 5/6 |
| PainMusculoskeletal and connective tissue disorders | 5/18 | 2/6 |
| CovidImmune system disorders | 0/18 | 1/6 |
| NumbnessNervous system disorders | 1/18 | 1/6 |
| Muscle crampsMusculoskeletal and connective tissue disorders | 3/18 | 0/6 |
| Hot flashesEndocrine disorders | 3/18 | 0/6 |
| HivesSkin and subcutaneous tissue disorders | 1/18 | 0/6 |
| DiarrheaGastrointestinal disorders | 1/18 | 0/6 |
| ConstipationGastrointestinal disorders | 1/18 | 0/6 |
| Acid regurgitationGastrointestinal disorders | 1/18 | 0/6 |
| Age, Categorical(Participants) | Alendronate | Zoledronic Acid | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 6 | 24 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Alendronate | Zoledronic Acid | Total |
|---|---|---|---|
| Mean | 38.7 ± 8.6 | 34.7 ± 6.3 | 37.7 ± 8.1 |
| Sex: Female, Male(Participants) | Alendronate | Zoledronic Acid | Total |
|---|---|---|---|
| Female | 18 | 6 | 24 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Alendronate | Zoledronic Acid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 18 | 6 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Alendronate | Zoledronic Acid | Total |
|---|---|---|---|
| United States | 18 | 6 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2018 to primary completion in Jun 2023, 64 months.
Results were first posted in May 2024, 10 months after primary completion.
Of 33 non-industry phase 2 interventional studies under Osteoporosis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's 64 months is close to that.
Counting every sponsor, half of 42 studies reached it within 47 months; a quarter within 29 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alendronate · Zoledronic Acid